clostridium%20difficile%20infection
CLOSTRIDIUM DIFFICILE INFECTION
Clostridium difficile infection is commonly associated with antibiotic treatment and is one of the most common nosocomial infections.
Symptoms usually start on days 4-9 of antibiotic treatment, but may also occur up to 8-10 weeks after discontinuation of antibiotics.
Discontinuation of antibiotics may be the only measure needed for patients with only mild diarrhea, no fever, no abdominal pain nor a high WBC count.
Cessation of antibiotics allows for reconstitution of the normal colonic microflora and markedly reduces risk of relapse.

Follow Up

Monitor Patient for Relapse

  • 20-25% of patients w/ C difficile infection will experience recurrent infection
    • Occurring <8 weeks after the onset of prior episode as long as symptoms of prior episode resolved after initial treatment was completed
  • Relapses are not usually due to development of antibiotic-resistant organisms
    • Usually due to germination of persistent spores in the colon after treatment or
    • Reinfection because of reingestion of the pathogen

Infection Control Measures

  • Proper handwashing between patient contacts must be observed
  • Isolate patients w/ C difficile-associated diarrhea
  • Use precautions when in contact w/ the infected patient & the environment
  • Objects & equipment must be properly disinfected
  • Educate patient & hospital staff regarding the disease
  • Judicious use of antibiotics must be exercised to prevent further cases of infection
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 14 Aug 2018
A new study reinforces the gut-brain connection in Alzheimer’s disease (AD), untangling the complex interplay between gut and brain health that could potentially lead to new therapies targeted at manipulating the gut microbiome to treat AD.
Roshini Claire Anthony, 6 days ago

Reducing the dose of regorafenib did little to affect the overall tolerability of the drug in patients with metastatic colorectal cancer (mCRC), according to the phase II REARRANGE* trial presented at ESMO GI 2019.